Literature DB >> 16249202

Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor.

Allen Rodgers1, Shameez Allie-Hamdulay, Graham Jackson.   

Abstract

BACKGROUND: The therapeutic action of citrate in the management of calcium oxalate urolithiasis has been attributed to the depletion of free calcium ions by complexation of the latter by citrate itself. However, little attention has been given to the nature of such complexes and the chemical conditions which control their formation because it is very difficult to measure them in solution. We therefore modelled the theoretical formation of these complexes in urine following administration of a citrate-containing preparation, using a powerful speciation program, JESS (Joint Expert Speciation System), which has been widely used to model metal-ligand equilibria in biological systems but which has hitherto not been applied in urolithiasis research. This program has an extensive database of thermodynamic constants and is able to calculate mixed ligand speciation.
METHODS: Urine data obtained before and after citrate administration in four groups of subjects (male and female normals and stone formers) were used as input for JESS to calculate the speciation of calcium, citrate and oxalate. The program was also used to examine the effects of varying different urinary components on the nature and concentration of the various species.
RESULTS: The speciation predicted the formation of a key calcium-citrate-phosphate species (previously unreported in urolithiasis research), which accounts for a significant percentage of the complexation of the free calcium. Moreover, the formation of this complex was found to be dependent on an increase in urinary pH rather than on an increase in urinary citrate concentration per se.
CONCLUSION: The therapeutic action of citrate in the management of calcium oxalate urolithiasis is due to the formation of a pH dependent calcium-citrate-phosphate complex which reduces the concentration of the free calcium ion species, thereby reducing the risk of stone formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249202     DOI: 10.1093/ndt/gfi211

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  24 in total

Review 1.  Pharmacotherapy of urolithiasis: evidence from clinical trials.

Authors:  Orson W Moe; Margaret S Pearle; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

2.  Effects of vitamin E ingestion on plasma and urinary risk factors for calcium oxalate urolithiasis in two population groups having different stone-risk profiles: evidence of different physiological handling mechanisms.

Authors:  Takalani Theka; Allen Rodgers; Sonja Lewandowski; Dawn Webber; Shameez Allie-Hamdulay
Journal:  Urol Res       Date:  2011-12-03

3.  Net Acid Excretion and Urinary Organic Anions in Idiopathic Uric Acid Nephrolithiasis.

Authors:  I Alexandru Bobulescu; Sun K Park; L H Richie Xu; Francisco Blanco; John Poindexter; Beverley Adams-Huet; Taylor L Davidson; Khashayar Sakhaee; Naim M Maalouf; Orson W Moe
Journal:  Clin J Am Soc Nephrol       Date:  2019-02-11       Impact factor: 8.237

Review 4.  Physicochemical mechanisms of stone formation.

Authors:  Allen L Rodgers
Journal:  Urolithiasis       Date:  2016-12-07       Impact factor: 3.436

Review 5.  Incomplete Distal Renal Tubular Acidosis and Kidney Stones.

Authors:  Daniel G Fuster; Orson W Moe
Journal:  Adv Chronic Kidney Dis       Date:  2018-07       Impact factor: 3.620

6.  Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis.

Authors:  Parveen Kumar; Andrew Bell; Tanecia Mitchell
Journal:  J Vis Exp       Date:  2021-02-09       Impact factor: 1.355

7.  Metabolic syndrome and the risk of calcium stones.

Authors:  Khashayar Sakhaee; Giovanna Capolongo; Naim M Maalouf; Andreas Pasch; Orson W Moe; John Poindexter; Beverley Adams-Huet
Journal:  Nephrol Dial Transplant       Date:  2012-01-13       Impact factor: 5.992

Review 8.  Hyperuricosuric calcium urolithiasis.

Authors:  Orson W Moe; Li Hao Richie Xu
Journal:  J Nephrol       Date:  2018-01-24       Impact factor: 3.902

Review 9.  Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

Authors:  Khashayar Sakhaee; Naim M Maalouf; Rajiv Kumar; Andreas Pasch; Orson W Moe
Journal:  Kidney Int       Date:  2010-12-01       Impact factor: 10.612

10.  Impact of Potassium Citrate vs Citric Acid on Urinary Stone Risk in Calcium Phosphate Stone Formers.

Authors:  Steeve Doizi; John R Poindexter; Margaret S Pearle; Francisco Blanco; Orson W Moe; Khashayar Sakhaee; Naim M Maalouf
Journal:  J Urol       Date:  2018-07-20       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.